RESUMEN
Experimental myasthenia gravis (MG) in animals, and in particular experimental autoimmune MG in rodents, serves as excellent models to study possible novel therapeutic modalities for MG. The current treatments for MG are based on cholinesterase inhibitors, general immunosuppressants, and corticosteroids, broad immunomodulatory therapies such as plasma exchange or intravenous immunoglobulins (IVIGs), and thymectomy for selected patients. This stresses the need for immunotherapies that would specifically or preferentially suppress the undesirable autoimmune response without widely affecting the entire immune system as most available treatments do. The available animal models for MG enable to perform preclinical studies in which novel therapeutic approaches can be tested. In this review, we describe the different therapeutic approaches that were so far tested in experimental models of MG and discuss their underlying mechanisms of action. These include antigen - acetylcholine receptor (AChR)-dependent treatments aimed at specifically abrogating the humoral and cellular anti-AChR responses as well as immunomodulatory approaches that could be used either alone or in conjunction with antigen-specific treatments or alternatively serve as steroid sparing agents. The antigen-specific treatments are based on fragments or peptides derived from the acetylcholine receptor (AChR) that would theoretically deviate the anti-AChR autoimmune response away from the muscle target or on ways to target AChR-specific T- and B- cell responses or antibodies. The immunomodulatory modalities include cell-based and non-cell-based ways to affect or manipulate key players in the autoimmune process such as regulatory T cells, dendritic cells, cytokine networks, and chemokine and costimulatory signaling as well as complement pathways. We also describe approaches that attempt to affect the cholinergic balance, which is impaired at the neuromuscular junction. In addition to enabling to test the feasibility of novel approaches, experimental MG enables to perform analyses of existing treatment modalities, which cannot be performed in human MG patients. These include studies on the mode of action of various immunosuppressants and on IVIGs. Hopefully, the vast repertoire of therapeutic approaches that are studied in experimental models of MG will pave the way to clinical studies that will eventually improve the management of MG.
Asunto(s)
Modelos Animales de Enfermedad , Inmunoglobulinas Intravenosas/uso terapéutico , Inmunosupresores/uso terapéutico , Miastenia Gravis Autoinmune Experimental/terapia , Miastenia Gravis/terapia , Animales , Eliminación de Componentes Sanguíneos , Quimioterapia Combinada , Humanos , Inmunoterapia , Linfocitos/inmunología , Miastenia Gravis/tratamiento farmacológico , Miastenia Gravis Autoinmune Experimental/tratamiento farmacológico , Receptores Colinérgicos/inmunología , Terapias en InvestigaciónRESUMEN
Alzheimer's disease (AD) is characterized by extracellular deposits of amyloid beta peptide (Abeta), a peptide that is generated upon proteolytic cleavage of amyloid precursor protein (APP). The events leading to the development of AD and their sequence are not yet fully understood. Protein kinase C (PKC) has been suggested to have a significant role in controlling neuronal degeneration and in the aberrant signal transduction taking place in AD. Several studies document a deficit in PKC levels and activity in brains of AD patients when compared with those of normal controls. Such a decrease in PKC could have serious implications since certain PKC isozymes were shown to drive the APP proteolytic cleavage into a non-amyloidogenic pathway. Reduced levels of distinct PKC isozymes could thus contribute to driving APP processing toward an amyloidogenic pathway. The direct cause for the down-regulation of PKC in AD brains is still unknown. In that respect, we tested in this study whether APP may play a role in PKC reduction. We show in three different cell lines (CHO, COS and BOSC) that overexpression of APP leads to decreased PKC levels. This decrease was found to be specific for the epsilon PKC isozyme whereas the levels of delta, alpha and conventional PKC remained unchanged. Furthermore, we observed this decrease for both active, membrane-associated and inactive, cytosolic epsilon PKC. APP-driven decrease in epsilon PKC is most likely mediated by a factor in the culture medium, since transfer of medium from cultured cells overexpressing APP to naïve, non-overexpressing cells, has also led to the selective decrease in epsilon PKC levels. Taken together, our results suggest that APP expression levels may play a role in the decrease of epsilon PKC levels in AD brains and could thus affect the responsiveness of AD brain tissues to growth factors and neurotransmitters.
Asunto(s)
Precursor de Proteína beta-Amiloide/fisiología , Regulación Enzimológica de la Expresión Génica/fisiología , Proteína Quinasa C-epsilon/genética , Proteína Quinasa C-epsilon/metabolismo , Animales , Línea Celular , Chlorocebus aethiops , Cricetinae , Cricetulus , Medios de Cultivo Condicionados/farmacología , Regulación Enzimológica de la Expresión Génica/efectos de los fármacos , Humanos , Ratones , Transporte de Proteínas/efectos de los fármacos , Transporte de Proteínas/fisiología , Acetato de Tetradecanoilforbol/análogos & derivados , Acetato de Tetradecanoilforbol/farmacología , TransfecciónRESUMEN
Interleukin-18 (IL-18) is a pleiotropic proinflammatory cytokine that plays an important role in interferon gamma (IFN-gamma) production and IL-12-driven Th1 phenotype polarization. Increased expression of IL-18 has been observed in several autoimmune diseases. In this study we have analyzed the role of IL-18 in an antibody-mediated autoimmune disease and elucidated the mechanisms involved in disease suppression mediated by blockade of IL-18, using experimental autoimmune myasthenia gravis (EAMG) as a model. EAMG is a T cell-regulated, antibody-mediated autoimmune disease in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. Th1- and Th2-type responses are both implicated in EAMG development. We show that treatment by anti-IL-18 during ongoing EAMG suppresses disease progression. The protective effect can be adoptively transferred to naive recipients and is mediated by increased levels of the immunosuppressive Th3-type cytokine TGF-beta and decreased AChR-specific Th1-type cellular responses. Suppression of EAMG is accompanied by down-regulation of the costimulatory factor CD40L and up-regulation of CTLA-4, a key negative immunomodulator. Our results suggest that IL-18 blockade may potentially be applied for immunointervention in myasthenia gravis.
Asunto(s)
Anticuerpos/uso terapéutico , Inmunoconjugados , Interleucina-18/antagonistas & inhibidores , Miastenia Gravis Autoinmune Experimental/terapia , Abatacept , Animales , Antígenos CD , Antígenos de Diferenciación/biosíntesis , Linfocitos B/inmunología , Ligando de CD40/metabolismo , Antígeno CTLA-4 , Células Cultivadas , Citocinas/biosíntesis , Progresión de la Enfermedad , Femenino , Hipersensibilidad Tardía/terapia , Inmunoglobulina G/biosíntesis , Interleucina-18/inmunología , Cinética , Activación de Linfocitos , Miastenia Gravis Autoinmune Experimental/inmunología , Ratas , Ratas Endogámicas Lew , Receptores Nicotínicos/inmunología , Linfocitos T/inmunología , Células TH1/inmunología , Factor de Crecimiento Transformador beta/biosíntesisRESUMEN
Myasthenia gravis (MG) and experimental autoimmune MG (EAMG) are T cell-dependent Ab-mediated autoimmune disorders, in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. Th1-type cells and costimulatory factors such as CD40 ligand (CD40L) contribute to disease pathogenesis by producing proinflammatory cytokines and by activating autoreactive B cells. In this study we demonstrate the capacity of CD40L blockade to modulate EAMG, and analyze the mechanism underlying this disease suppression. Anti-CD40L Abs given to rats at the chronic stage of EAMG suppress the clinical progression of the autoimmune process and lead to a decrease in the AChR-specific humoral response and delayed-type hypersensitivity. The cytokine profile of treated rats suggests that the underlying mechanism involves down-regulation of AChR-specific Th1-regulated responses with no significant effect on Th2- and Th3-regulated AChR-specific responses. EAMG suppression is also accompanied by a significant up-regulation of CTLA-4, whereas a series of costimulatory factors remain unchanged. Adoptive transfer of splenocytes from anti-CD40L-treated rats does not protect recipient rats against subsequently induced EAMG. Thus it seems that the suppressed progression of chronic EAMG by anti-CD40L treatment does not induce a switch from Th1 to Th2/Th3 regulation of the AChR-specific immune response and does not induce generation of regulatory cells. The ability of anti-CD40L treatment to suppress ongoing chronic EAMG suggests that blockade of CD40L may serve as a potential approach for the immunotherapy of MG and other Ab-mediated autoimmune diseases.
Asunto(s)
Antígenos de Diferenciación/biosíntesis , Ligando de CD40/inmunología , Regulación hacia Abajo/inmunología , Sueros Inmunes/administración & dosificación , Inmunoconjugados , Inmunosupresores/administración & dosificación , Miastenia Gravis Autoinmune Experimental/inmunología , Células TH1/inmunología , Regulación hacia Arriba/inmunología , Abatacept , Animales , Especificidad de Anticuerpos , Antígenos CD , Linfocitos B/inmunología , Linfocitos B/metabolismo , Antígeno CTLA-4 , Diferenciación Celular/inmunología , Células Cultivadas , Enfermedad Crónica , Citocinas/biosíntesis , Femenino , Humanos , Hipersensibilidad Tardía/inmunología , Inmunoglobulina G/biosíntesis , Isotipos de Inmunoglobulinas/biosíntesis , Inyecciones Intraperitoneales , Inyecciones Subcutáneas , Activación de Linfocitos/inmunología , Miastenia Gravis Autoinmune Experimental/patología , Miastenia Gravis Autoinmune Experimental/prevención & control , Ratas , Ratas Endogámicas Lew , Receptores Colinérgicos/administración & dosificación , Receptores Colinérgicos/inmunología , Células TH1/metabolismo , Células TH1/patología , Células Th2/inmunología , Células Th2/metabolismo , Torpedo/inmunologíaRESUMEN
Acetylcholine receptor (AChR) is the major autoantigen in myasthenia gravis (MG) and experimental autoimmune MG (EAMG). Here we analyze the mechanisms involved in suppression of ongoing EAMG in rats by nasal administration of a recombinant fragment from the human AChR alpha-subunit. We demonstrate that such a fragment, expressed without a fusion partner, confers nasal tolerance that can be adoptively transferred. Our observations suggest that the underlying mechanism of this nasal tolerance is active suppression involving a shift from a Th1 to a Th2/Th3-regulated AChR-specific response which may be mediated by down regulation of costimulatory factors.
Asunto(s)
Tolerancia Inmunológica/inmunología , Inmunoterapia , Miastenia Gravis Autoinmune Experimental/inmunología , Miastenia Gravis Autoinmune Experimental/terapia , Receptores Colinérgicos/inmunología , Administración Intranasal , Animales , Presentación de Antígeno/inmunología , Femenino , Tolerancia Inmunológica/efectos de los fármacos , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/farmacología , Ratas , Ratas Endogámicas Lew , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/farmacología , Células TH1/inmunología , Células Th2/inmunologíaRESUMEN
We recently demonstrated that oral or nasal administration of recombinant fragments of the acetylcholine receptor (AChR) prevents the induction of experimental autoimmune myasthenia gravis (EAMG) and suppresses ongoing EAMG in rats. We have now studied the role of spatial conformation of these recombinant fragments in determining their tolerogenicity. Two fragments corresponding to the extracellular domain of the human AChR alpha-subunit and differing in conformation were tested: Halpha1-205 expressed with no fusion partner and Halpha1-210 fused to thioredoxin (Trx), and designated Trx-Halpha1-210. The conformational similarity of the fragments to intact AChR was assessed by their reactivity with alpha-bungarotoxin and with anti-AChR mAbs, specific for conformation-dependent epitopes. Oral administration of the more native fragment, Trx-Halpha1-210, at the acute phase of disease led to exacerbation of EAMG, accompanied by an elevation of AChR-specific humoral and cellular reactivity, increased levels of Th1-type cytokines (IL-2, IL-12), decreased levels of Th2 (IL-10)- or Th3 (TGF-beta)-type cytokines, and higher expression of costimulatory factors (CD28, CTLA4, B7-1, B7-2, CD40L, and CD40). On the other hand, oral administration of the less native fragments Halpha1-205 or denatured Trx-Halpha1-210 suppressed ongoing EAMG and led to opposite changes in the immunological parameters. It thus seems that native conformation of AChR-derived fragments renders them immunogenic and immunopathogenic and therefore not suitable for treatment of myasthenia gravis. Conformation of tolerogens should therefore be given careful attention when considering oral tolerance for treatment of autoimmune diseases.
Asunto(s)
Tolerancia Inmunológica , Inmunoconjugados , Miastenia Gravis/inmunología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/inmunología , Receptores Nicotínicos/química , Receptores Nicotínicos/inmunología , Proteínas Recombinantes/química , Proteínas Recombinantes/inmunología , Abatacept , Administración Oral , Animales , Antígenos CD/biosíntesis , Antígenos de Diferenciación/biosíntesis , Linfocitos B/inmunología , Antígeno B7-1/biosíntesis , Antígeno B7-2 , Antígenos CD28/biosíntesis , Antígenos CD40/biosíntesis , Ligando de CD40/biosíntesis , Antígeno CTLA-4 , Células Cultivadas , Citocinas/biosíntesis , Femenino , Humanos , Tolerancia Inmunológica/genética , Inmunohistoquímica , Activación de Linfocitos/genética , Glicoproteínas de Membrana/biosíntesis , Fragmentos de Péptidos/administración & dosificación , Conformación Proteica , Ratas , Ratas Endogámicas Lew , Receptores Nicotínicos/administración & dosificación , Receptores Nicotínicos/genética , Proteínas Recombinantes/administración & dosificación , Linfocitos T/inmunología , Células TH1/inmunología , Células TH1/metabolismoRESUMEN
Myasthenia gravis (MG) is an autoimmune disorder in which the nicotinic acetylcholine receptor (AChR) is the major autoantigen. In an attempt to develop an antigen-specific therapy for MG, we administered a nonmyasthenogenic recombinant fragment of AChR orally to rats. This fragment, corresponding to the extracellular domain of the human AChR alpha-subunit (Halpha1-205), protected rats from subsequently induced experimental autoimmune myasthenia gravis (EAMG) and suppressed ongoing EAMG when treatment was initiated during either the acute or chronic phases of disease. Prevention and suppression of EAMG were accompanied by a significant decrease in AChR-specific humoral and cellular responses. The underlying mechanism for the Halpha1-205-induced oral tolerance seems to be active suppression, mediated by a shift from a T-helper 1 (Th1) to a Th2/Th3 response. This shift was assessed by changes in the cytokine profile, a deviation of anti-AChR IgG isotypes from IgG2 to IgG1, and a suppressed AChR-specific delayed-type hypersensitivity response. Our results in experimental myasthenia suggest that oral administration of AChR-specific recombinant fragments may be considered for antigen-specific immunotherapy of myasthenia gravis.
Asunto(s)
Miastenia Gravis/terapia , Fragmentos de Péptidos/inmunología , Receptores Colinérgicos/inmunología , Administración Oral , Animales , Femenino , Tolerancia Inmunológica , Ovalbúmina/inmunología , Ratas , Ratas Endogámicas Lew , Proteínas Recombinantes/inmunologíaRESUMEN
Brief periods of cardiac ischemia trigger protection from subsequent prolonged ischemia (preconditioning). epsilon Protein kinase C (epsilonPKC) has been suggested to mediate preconditioning. Here, we describe an epsilonPKC-selective agonist octapeptide, psiepsilon receptor for activated C-kinase (psiepsilonRACK), derived from an epsilonPKC sequence homologous to its anchoring protein, epsilonRACK. Introduction of psiepsilonRACK into isolated cardiomyocytes, or its postnatal expression as a transgene in mouse hearts, increased epsilonPKC translocation and caused cardio-protection from ischemia without any deleterious effects. Our data demonstrate that epsilonPKC activation is required for protection from ischemic insult and suggest that small molecules that mimic this epsilonPKC agonist octapeptide provide a powerful therapeutic approach to protect hearts at risk for ischemia.
Asunto(s)
Cardiotónicos/uso terapéutico , Isoenzimas/metabolismo , Isquemia Miocárdica/prevención & control , Oligopéptidos/uso terapéutico , Proteína Quinasa C/metabolismo , Receptores de Superficie Celular/uso terapéutico , Secuencia de Aminoácidos , Animales , Transporte Biológico , Cardiotónicos/síntesis química , Cardiotónicos/farmacología , Muerte Celular/efectos de los fármacos , Técnicas In Vitro , Masculino , Ratones , Ratones Transgénicos , Datos de Secuencia Molecular , Oligopéptidos/síntesis química , Oligopéptidos/farmacología , Proteína Quinasa C-epsilon , Ratas , Ratas Wistar , Receptores de Cinasa C ActivadaRESUMEN
Myasthenia gravis (MG) and experimental autoimmune myasthenia gravis (EAMG) are antibody-mediated autoimmune diseases in which the nicotinic acetylcholine receptor (AcChoR) is the major autoantigen. The immune response in these diseases is heterogeneous and is directed to a wide variety of T and B cell epitopes of AcChoR. Candidate molecules for specific immunotherapy of MG should, therefore, have a broad specificity. We used recombinant fragments of the human AcChoR, encompassing the extracellular domain of the alpha-subunit, or shorter fragments derived from it, in experiments to modulate EAMG. We have demonstrated that intranasal administration of these recombinant fragments, which represent a major portion of epitopes involved in MG, prevents the induction of EAMG in rats and immunosuppresses an ongoing disease, as assessed by clinical symptoms, weight loss, and muscle AcChoR content. These effects on EAMG were accompanied by a marked reduction in the proliferative T-cell response and IL-2 production in response to AcChoR, in reduced anti-self AcChoR antibody titers and in an isotype switch of AcChoR-specific antibodies, from IgG2 to IgG1. We conclude that nasal tolerance induced by appropriate recombinant fragments of human AcChoR is effective in suppressing EAMG and might possibly be considered as a therapeutic modality for MG.
Asunto(s)
Activación de Linfocitos , Miastenia Gravis/inmunología , Miastenia Gravis/prevención & control , Receptores Colinérgicos/inmunología , Administración Intranasal , Animales , Modelos Animales de Enfermedad , Órgano Eléctrico/fisiología , Femenino , Humanos , Tolerancia Inmunológica , Inmunoglobulina G/sangre , Isotipos de Inmunoglobulinas/sangre , Interleucina-2/biosíntesis , Ganglios Linfáticos/inmunología , Sustancias Macromoleculares , Mycobacterium tuberculosis/inmunología , Ratas , Ratas Endogámicas Lew , Receptores Colinérgicos/administración & dosificación , Receptores Colinérgicos/uso terapéutico , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/inmunología , Proteínas Recombinantes/uso terapéutico , TorpedoRESUMEN
Signal transduction cascades involve multiple enzymes and are orchestrated by selective protein-protein interactions that are essential for the progression of intracellular signaling events. Modulators of these protein-protein interactions have been used to dissect the role of individual components of each signaling cascade. We describe several methods that have been developed for the identification of peptides that inhibit the interaction between signaling proteins and hence selectively modulate their functions. Such peptide modulators provide important tools for basic research and have great potential as leads for the development of new classes of therapeutic drugs.
Asunto(s)
Péptidos/metabolismo , Unión Proteica , Transducción de Señal , Secuencia de Aminoácidos , Datos de Secuencia Molecular , Biblioteca de Péptidos , Péptidos/química , Homología de Secuencia de AminoácidoAsunto(s)
Miastenia Gravis/prevención & control , Fragmentos de Péptidos/uso terapéutico , Receptores Colinérgicos/uso terapéutico , Linfocitos T/inmunología , Animales , Anticuerpos Monoclonales , Humanos , Inmunización Pasiva , Activación de Linfocitos/efectos de los fármacos , Miastenia Gravis/inmunología , Ratas , Receptores Colinérgicos/inmunología , Proteínas Recombinantes/uso terapéutico , TorpedoRESUMEN
Myasthenia gravis (MG) is a neuromuscular disorder of man caused by a humoral response to the acetylcholine receptor (AChR). Most of the antibodies in MG and in experimental autoimmune myasthenia gravis (EAMG) are directed to the extracellular portion of the AChR alpha subunit, and within it, primarily to the main immunogenic region (MIR). We have cloned and expressed recombinant fragments, corresponding to the entire extracellular domain of the AChR alpha subunit (H alpha1-210), and to portions of it that encompass either the MIR (H alpha1-121) or the ligand binding site of AChR (H alpha122-210), and studied their ability to interfere with the immunopathological anti-AChR response in vitro and in vivo. All fragments were expressed as fusion proteins with glutathione S-transferase. Fragments H alpha1-121 and H alpha1-210 protected AChR in TE671 cells against accelerated degradation induced by the anti-MIR monoclonal antibody (mAb)198 in a dose-dependent manner. Moreover, these fragments had a similar effect on the antigenic modulation of AChR by other anti-MIR mAb and by polyclonal rat anti-AChR antibodies. Fragments H alpha1-121 and H alpha1-210 were also able to modulate in vivo muscle AChR loss and development of clinical symptoms of EAMG, passively transferred to rats by mAb 198. Fragment H alpha122-210 did not have such a protective activity. Our results suggest that the appropriate recombinant fragments of the human AChR may be employed in the future for antigen-specific therapy of myasthenia.
Asunto(s)
Anticuerpos Monoclonales/biosíntesis , Autoanticuerpos/biosíntesis , Miastenia Gravis/inmunología , Fragmentos de Péptidos/genética , Receptores Colinérgicos/genética , Receptores Colinérgicos/inmunología , Proteínas Recombinantes/farmacología , Traslado Adoptivo , Animales , Modulación Antigénica/genética , Western Blotting , Línea Celular , Ensayo de Inmunoadsorción Enzimática , Femenino , Humanos , Miastenia Gravis/etiología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/farmacología , Ratas , Ratas Endogámicas Lew , Receptores Colinérgicos/fisiología , Proteínas Recombinantes/químicaRESUMEN
We have employed a hexapeptide phage-epitope library to identify epitopes for a mAb (mAb 5.14), which is directed to a determinant within a highly immunogenic, cytoplasmic region of the alpha-subunit of acetylcholine receptor (AChR). We have selected two different peptide-presenting phages (SWDDIR-phage and LWILTR-phage) which interact specifically with mAb 5.14. This interaction is specifically inhibited by AChR and by synthetic peptides corresponding to the hexapeptides presented by the selected phages. Although mAb 5.14 binds to AChR in its native as well as its denatured form, the selected hexapeptides do not exist as such in the AChR molecule. However, three amino acid sequence homologies with these hexapeptides were shown to be present in the cytoplasmic region of Torpedo AChR. By extending the selected hexapeptides, at one or both ends, with amino acid residues flanking the hexapeptides in the phage, we obtained mimotopes with an up to two order of magnitude higher affinity to the Ab. These extended peptides were able to efficiently block the binding of mAb 5.14 to both peptide-presenting phages, and to AChR.
Asunto(s)
Epítopos Inmunodominantes/aislamiento & purificación , Receptores Colinérgicos/inmunología , Secuencia de Aminoácidos , Animales , Anticuerpos Antiidiotipos/inmunología , Anticuerpos Monoclonales/inmunología , Presentación de Antígeno , Bacteriófagos/genética , Unión Competitiva/inmunología , Western Blotting , Biblioteca de Genes , Datos de Secuencia Molecular , Oligopéptidos/inmunología , TorpedoRESUMEN
The mRNA levels of acetylcholine receptor (AChR) and myogenic factors were followed during embryonic development of Torpedo skeletal muscle and its homologue, the electric organ. A different developmental pattern of AChR gene expression was found in these two tissues: a slight decrease in the muscle, and a marked increase, concomitant with synapse formation, in the electric organ. However, the developmental pattern of MyoD and MRF4 mRNA levels was similar in both tissues, with no significant changes during development. This is in contrast with the sharp increase in the expression of AChR in the electric organ and may suggest that the burst in the expression of AChR during the differentiation of myotubes into electrocytes is not regulated by changes in the myogenic factor mRNA levels.
Asunto(s)
Expresión Génica/fisiología , Factores Reguladores Miogénicos/metabolismo , Receptores Colinérgicos/metabolismo , Torpedo/embriología , Animales , Northern Blotting , Sondas de ADN , Órgano Eléctrico/embriología , Órgano Eléctrico/metabolismo , Embrión no Mamífero , Femenino , Factores Reguladores Miogénicos/genética , ARN Mensajero/biosíntesis , Receptores Colinérgicos/genética , Torpedo/metabolismoRESUMEN
The passive transfer of myasthenia gravis by injection of mAb against muscle acetylcholine receptor (AChR) alpha-subunit, results in increased expression of AChR subunit genes, mainly at synaptic regions. The gene expression of AChR and of other muscle-specific proteins is regulated in a similar manner in passively transferred experimental autoimmune myasthenia gravis (EAMG) and in AChR-induced EAMG. Administration of AChR-specific mAb leads to a significant reduction in muscle AChR content and to an elevation in the mRNA levels corresponding to the adult, synaptic type of the receptor, as shown by Northern blot and in situ hybridization analyses. The mRNA levels of the myogenic factors myogenin and MRF4 are also increased moderately, whereas MyoD transcript levels remain unchanged. Thus, passive transfer of EAMG by mAb directed to defined epitopes of AChR alpha-subunit provides a suitable model for analyzing and following the cascade of molecular events triggered by anti-AChR immunopathologic antibodies and may shed light on the regulatory mechanisms underlying the human disease as well.
Asunto(s)
Regulación de la Expresión Génica , Miastenia Gravis/metabolismo , Proteína MioD/genética , Receptores Colinérgicos/genética , Factores de Transcripción/genética , Animales , Anticuerpos Monoclonales/inmunología , Femenino , Desnervación Muscular , Músculos/metabolismo , ARN Mensajero/análisis , Ratas , Ratas Endogámicas Lew , Receptores Colinérgicos/fisiologíaRESUMEN
Synthetic peptides corresponding to selected sequences from the nicotinic acetylcholine receptor (AChR) were employed to identify possible antigenic determinants within the receptor which can modulate the anti-AChR response and experimental autoimmune myasthenia gravis (EAMG). Immunization of rabbits with peptides T alpha 73-89, T alpha 351-368, T delta 354-367 and H alpha 351-368, prior to AChR inoculation, affected the course of EAMG in six out of eight rabbits. These six protected rabbits survived three inoculations of AChR and survived for at least five months after the third injection with AChR, whereas control rabbits died following one or two injections of AChR. The survival of peptide-preimmunized rabbits injected with AChR seemed to correlate with the antibody specificities in immunoblots. Following AChR inoculation there was a shift in reactivity, from a subunit-restricted response, to reactivity with all subunits of the receptor. This shift was delayed in protected rabbits. This may indicate that the reactivity with the entire Torpedo receptor molecule represents a loss of tolerance to AChR which culminates in the autoimmune disease, EAMG.
Asunto(s)
Formación de Anticuerpos/efectos de los fármacos , Especificidad de Anticuerpos/efectos de los fármacos , Miastenia Gravis/inmunología , Fragmentos de Péptidos/inmunología , Receptores Colinérgicos/inmunología , Secuencia de Aminoácidos , Animales , Modelos Animales de Enfermedad , Epítopos/inmunología , Inmunización Pasiva , Datos de Secuencia Molecular , Miastenia Gravis/prevención & control , Radioinmunoensayo , TorpedoRESUMEN
Antibodies to a synthetic peptide corresponding to residues 346-359 of the Torpedo acetylcholine receptor (AChR) gamma subunit, were employed to compare the adult and embryonic receptor. This peptide contains a consensus phosphorylation site for cAMP-dependent protein kinase (PKA). The anti-peptide antibodies discriminated between adult and embryonic AChRs, and reacted preferentially with the adult gamma form. These observed immunological differences did not seem to stem from different phosphorylation states. Our results suggest that the embryonic Torpedo AChR may have a gamma-like subunit that differs from the known adult form of this subunit, at least in the specific region that contains the phosphorylation site for PKA.
Asunto(s)
Fragmentos de Péptidos/química , Receptores Colinérgicos/química , Torpedo/metabolismo , Secuencia de Aminoácidos , Animales , Órgano Eléctrico/química , Datos de Secuencia Molecular , Fosforilación , Alineación de Secuencia , Torpedo/embriología , Torpedo/crecimiento & desarrolloRESUMEN
Polymorphisms of the Ig H chain V region (VH) genes were examined with probes from the coding and flanking regions of a gene from the largest VH gene family, VHIII. The 5'-flanking probe gave the simplest pattern and revealed the largest number of polymorphic fragments. Analysis of unrelated individuals and of families identified five polymorphic loci. Two alleles were detected for each of two of the loci, whereas a polymorphic band was scored as present or absent for the other three loci. The polymorphic fragments segregated in the expected Mendelian fashion and parental haplotypes could be assigned in all cases. Comparison of the patterns obtained with the flanking and coding region probes suggests that the human VHIII gene family is highly polymorphic and may contain several hundred V genes. This method, as well as the polymorphism detected, can be used to investigate the organization and germ-line variation of H chain V genes and their inheritance in normal individuals and in individuals with immunologic disorders.